Allogeneic bone marrow transplantation (BMT) for acquired severe aplastic anaemia (SAA) in children.
The SAA Registry of the EBMT now contains data on 171 children younger than 15 years of age with acquired SAA and undergoing BMT between 1970 and 1988. The overall actuarial survival is 63% at 10 years. In a multivariate Cox analysis, the year of transplant was the most important prognostic factor with a significant advantage for children grafted in 1984-88 (81%) vs 1981-83 (67%) and 1970-80 (41%) (p = 0.02). Cyclosporine A given for GVHD prophylaxis, no treatment before transplant and an interval less than 90 days from diagnosis to BMT were all favourable variables in univariate analysis. As regard to transplant procedures, the better results were obtained using Cyclophosphamide and Cyclosporine A (78%) followed by Cyclophosphamide plus irradiation plus Cyclosporine A (77%). Sex, etiology and the severity of the aplasia had no impact on survival in both uni and multivariate analysis.
Locasciulli
A
A
Vossen
J
J
Bacigalupo
A
A
Hows
J
J
VanLint
M T
MT
Gluckman
E
E
Nissen
C
C
McCann
S
S
de Planque
M
M
van'tVeer
L
L
D000293:Adolescent; D000741:Anemia, Aplastic / Q000188:drug therapy / Q000601:surgery*; D016026:Bone Marrow Transplantation; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000627:therapeutic use; D003524:Cyclosporins / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D015337:Multicenter Studies as Topic; D012042:Registries; D014184:Transplantation, Homologous
D003524:Cyclosporins; D003520:Cyclophosphamide